0C8 Stock Overview Develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Catalent, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Catalent Historical stock prices Current Share Price US$59.93 52 Week High US$60.22 52 Week Low US$38.05 Beta 1.14 1 Month Change 8.37% 3 Month Change 10.84% 1 Year Change 57.50% 3 Year Change -43.46% 5 Year Change 19.86% Change since IPO 293.27%
Recent News & Updates
Catalent, Inc.(NYSE:CTLT) dropped from FTSE All-World Index (USD) Dec 20 Catalent, Inc Announces Board Changes Novo Holdings A/S completed the acquisition of Catalent, Inc. (NYSE:CTLT) from a group of shareholders. Dec 18
Catalent, Inc. announced delayed annual 10-K filing Aug 31
Full year 2024 earnings released: US$5.76 loss per share (vs US$1.41 loss in FY 2023) Aug 30
New minor risk - Insider selling Aug 02 See more updates
Catalent, Inc.(NYSE:CTLT) dropped from FTSE All-World Index (USD) Dec 20 Catalent, Inc Announces Board Changes Novo Holdings A/S completed the acquisition of Catalent, Inc. (NYSE:CTLT) from a group of shareholders. Dec 18
Catalent, Inc. announced delayed annual 10-K filing Aug 31
Full year 2024 earnings released: US$5.76 loss per share (vs US$1.41 loss in FY 2023) Aug 30
New minor risk - Insider selling Aug 02
Insufficient new directors May 12
Catalent, Inc. announced delayed 10-Q filing Feb 13 Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million. Feb 06
Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million. Feb 05
Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024 Jan 27
Catalent, Inc. Announces Executive Changes Jan 17
Catalent, Inc., Annual General Meeting, Jan 25, 2024 Dec 16 Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024
Catalent, Inc. announced delayed 10-Q filing Nov 14
Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023 Nov 01
Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023 Sep 19
Catalent Receives NYSE Notice Regarding Late Form 10-K Filing Sep 16
Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors Sep 12
Catalent, Inc. announced delayed annual 10-K filing Sep 01
Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022) Aug 30 Catalent, Inc. Announces Board Changes
Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023 Aug 24
Insufficient new directors Aug 11
Catalent, Inc. Announces Executive Changes Aug 02
Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index Jun 25 Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023
Catalent Regains Compliance with NYSE Continued Listing Standards Jun 14 Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023 Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023
Catalent, Inc. announced delayed 10-Q filing May 12
Now 37% undervalued after recent price drop May 09
Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023 May 09
Insider recently sold €66k worth of stock May 04
Investor sentiment improves as stock rises 18% May 03
Now 22% undervalued after recent price drop Apr 14
Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary Feb 14
Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023 Feb 08
Second quarter 2023 earnings released: EPS: US$0.45 (vs US$0.51 in 2Q 2022) Feb 08
Danaher Reportedly Expresses Takeover Interest in Catalent Feb 07
Investor sentiment improves as stock rises 36% Feb 07
Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023 Jan 21
Now 20% undervalued after recent price drop Jan 19
Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America Jan 18
Catalent, Inc. Announces Director Changes Dec 20
Investor sentiment improved over the past week Dec 02
Investor sentiment deteriorated over the past week Nov 08
Insider recently sold €163k worth of stock Nov 03
First quarter 2023 earnings released Nov 02
Catalent, Inc. Revises Revenue Guidance for the Full Year 2023 Nov 02
Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022 Oct 18
Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million. Oct 05
Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer Sep 20
Now 21% undervalued after recent price drop Sep 17
Catalent, Inc., Annual General Meeting, Oct 27, 2022 Sep 17
Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021) Aug 30 Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022
Executive Chair of the Board recently sold €4.0m worth of stock Aug 28
Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million. Aug 11
Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022 Aug 06
Executive Chair of the Board recently sold €1.0m worth of stock Jul 30 Catalent, Inc. Announces Board Changes
Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022 May 05 Shareholder Returns 0C8 DE Pharmaceuticals DE Market 7D 2.4% -2.2% -2.0% 1Y 57.5% -15.8% 6.8%
See full shareholder returns
Return vs Market: 0C8 exceeded the German Market which returned 9.2% over the past year.
Price Volatility Is 0C8's price volatile compared to industry and market? 0C8 volatility 0C8 Average Weekly Movement 1.9% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0C8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0C8's weekly volatility (2%) has been stable over the past year.
About the Company Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Show more Catalent, Inc. Fundamentals Summary How do Catalent's earnings and revenue compare to its market cap? 0C8 fundamental statistics Market cap €10.99b Earnings (TTM ) -€393.80m Revenue (TTM ) €4.22b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0C8 income statement (TTM ) Revenue US$4.42b Cost of Revenue US$3.46b Gross Profit US$965.00m Other Expenses US$1.38b Earnings -US$413.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.28 Gross Margin 21.82% Net Profit Margin -9.34% Debt/Equity Ratio 130.0%
How did 0C8 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/17 12:53 End of Day Share Price 2024/12/17 00:00 Earnings 2024/09/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Catalent, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Sel Hardy CFRA Equity Research Parth Talsania Equisights
Show 11 more analysts 
